Phase II Study of Concurrent Capecitabine and External Beam Radiotherapy for Pain Control of Bone Metastases of Breast Cancer Origin |
| |
| Authors: | Yulia Kundel Nicola J. Nasser Ofer Purim Rinat Yerushalmi Eyal Fenig Raphael M. Pfeffer Salomon M. Stemmer Shulamith Rizel Zvi Symon Bella Kaufman Aaron Sulkes Baruch Brenner |
| |
| Affiliation: | 1. Institue of Oncology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel.; 2. Institute of Oncology, Chaim Sheba Medical Center, Tel Hashomer, Israel.; 3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; University Clinic of Navarra, Spain, |
| |
| Abstract: | BackgroundPain from bone metastases of breast cancer origin is treated with localized radiation. Modulating doses and schedules has shown little efficacy in improving results. Given the synergistic therapeutic effect reported for combined systemic chemotherapy with local radiation in anal, rectal, and head and neck malignancies, we sought to evaluate the tolerability and efficacy of combined capecitabine and radiation for palliation of pain due to bone metastases from breast cancer.Methodology/Principal FindingsTwenty-nine women with painful bone metastases from breast cancer were treated with external beam radiation in 10 fractions of 3 Gy, 5 fractions a week for 2 consecutive weeks. Oral capecitabine 700 mg/m2 twice daily was administered throughout radiation therapy. Rates of complete response, defined as a score of 0 on a 10-point pain scale and no increase in analgesic consumption, were 14% at 1 week, 38% at 2 weeks, 52% at 4 weeks, 52% at 8 weeks, and 48% at 12 weeks. Corresponding rates of partial response, defined as a reduction of at least 2 points in pain score without an increase in analgesics consumption, were 31%, 38%, 28%, 34% and 38%. The overall response rate (complete and partial) at 12 weeks was 86%. Side effects were of mild intensity (grade I or II) and included nausea (38% of patients), weakness (24%), diarrhea (24%), mucositis (10%), and hand and foot syndrome (7%).Conclusions/SignificanceExternal beam radiation with concurrent capecitabine is safe and tolerable for the treatment of pain from bone metastases of breast cancer origin. The overall and complete response rates in our study are unusually high compared to those reported for radiation alone. Further evaluation of this approach, in a randomized study, is warranted.Trial RegistrationClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT01784393","term_id":"NCT01784393"}}NCT01784393{"type":"clinical-trial","attrs":{"text":"NCT01784393","term_id":"NCT01784393"}}NCT01784393 |
| |
| Keywords: | |
|
|
